ANAB241220P22500
- 7.20
- +1.20+20.00%
AnaptysBio Newsroom
Wells Fargo Maintains Overweight on AnaptysBio, Lowers Price Target to $40
AnaptysBio Price Target Cut to $36.00/Share From $90.00 by Guggenheim
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $36
Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $40
Buy Rating on AnaptysBio: Strategic Focus on Rosnilimab Amidst Stock Valuation Opportunity
AnaptysBio's Atopic Dermatitis Trial of BTLA Agonist Misses Endpoints
Express News | AnaptysBio Inc : H.c. Wainwright Cuts to Neutral Rating; Cuts Target Price to $19 From $52
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care
Top Midday Decliners
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $32
AnaptysBio (ANAB) Receives a Buy From TD Cowen
AnaptysBio Analyst Ratings
Hold Rating on AnaptysBio Amidst Setbacks in ANB032 and Rosnilimab Efficacy
HC Wainwright Downgrades AnaptysBio to Neutral From Buy, $19 Price Target
AnaptysBio Down Nearly 33%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk
Wedbush Cuts Price Target on AnaptysBio to $40 From $42, Maintains Outperform Rating
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall
Express News | AnaptysBio Shares Fall 37.9% Premarket as Co Abandons Eczema Drug Development After Mid-Stage Trial Failure